3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
1
Status
Completed
3
Terminated
2
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Breast
3
Gastrointestinal
2
Genitourinary
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
226
Lung Neoplasms
78
Neoplasms
37
Mesothelioma
23
Mesothelioma, Malignant
21
Neoplasm Metastasis
20
Breast Neoplasms
18
Adenocarcinoma of Lung
18
Head and Neck Neoplasms
13
Colorectal Neoplasms
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Ovarian Neoplasms
11
Carcinoma
8
Uterine Cervical Neoplasms
6
Non-Squamous Non-Small Cell Lung Cancer
6
Adenocarcinoma, Bronchiolo-Alveolar
6
Adenocarcinoma
6
Unspecified Adult Solid Tumor, Protocol Specific
5
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Meningeal Carcinomatosis
5
Brain Neoplasms
5
Urinary Bladder Neoplasms
4
Small Cell Lung Carcinoma
4
Recurrence
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Laryngeal Diseases
4
Endometrial Neoplasms
4
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
Pemetrexed
×
Clear all
NCT03396445
2025-11-05
MK-5890-001
Merck Sharp & Dohme LLC
Phase 1
Completed
182 enrolled
36 charts
NCT03267316
2024-08-22
CANFOUR
Cantargia AB
Phase 1/2
Completed
167 enrolled
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts